TNFSF10 and pancreatic neoplasm: The native TRAIL formulation, dulanermin, was not clinically evaluated for PDAC, but agonistic TRAIL receptor Abs were shown to induce apoptosis in vitro and in pancreatic cancer xenograft models in vivo76,77.